Serum activin A and B levels predict outcome in patients with acute respiratory failure: A prospective cohort study

Critical Care

Volumn 17, Issue 5, 2013, Pages

  de Kretser, David M ^a   Bensley, Jonathan G ^a   Pettilä, Ville ^b   Linko, Rita ^b   Hedger, Mark P ^a   Hayward, Susan ^a   Allan, Carolyn A ^c   McLachlan, Robert I ^c   Ludlow, Helen ^d   Phillips, David J ^a  

^a MONASH UNIVERSITY   (Australia)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d OXFORD BROOKES UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; FOLLISTATIN; MYELOPID; ACTIVIN; BIOLOGICAL MARKER;

ACUTE RESPIRATORY FAILURE; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BODY HEIGHT; COHORT ANALYSIS; CRITICALLY ILL PATIENT; DIAGNOSIS RELATED GROUP; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ETHNICITY; FEMALE; HIP CIRCUMFERENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENSTRUAL CYCLE; MIDDLE AGED; MORTALITY; NORMAL HUMAN; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SCORING SYSTEM; SEX DIFFERENCE; SURVIVAL; WAIST CIRCUMFERENCE; YOUNG ADULT; ACUTE DISEASE; APACHE; BLOOD; FINLAND; RESPIRATORY FAILURE;

ACTIVINS; ACUTE DISEASE; ADOLESCENT; ADULT; AGED; APACHE; BIOLOGICAL MARKERS; FEMALE; FINLAND; FOLLISTATIN; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RESPIRATORY INSUFFICIENCY;

EID: 84886735949     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13093     Document Type: Article

References (50)

1. Demoule A, Girou E, Richard JC, Taille S, Brochard L. Increased use of noninvasive ventilation in French intensive care units. Intensive Care Med 2006, 32:1747-1755. 10.1007/s00134-006-0229-z, 16799775.
2. Flaatten H, Gjerde S, Guttormsen AB, Haugen O, Hoivik T, Onarheim H, Aardal S. Outcome after acute respiratory failure is more dependent on dysfunction in other vital organs than on the severity of the respiratory failure. Crit Care 2003, 7:R72. 10.1186/cc2331, 270698, 12930559.
3. Linko R, Okkonen M, Pettila V, Perttila J, Parviainen I, Ruokonen E, Tenhunen J, Ala-Kokko T, Varpula T,. group FI-s Acute respiratory failure in intensive care units. FINNALI: a prospective cohort study. Intensive Care Med 2009, 35:1352-1361. 10.1007/s00134-009-1519-z, 19526218, group FI-s.
4. Roupie E, Lepage E, Wysocki M, Fagon JY, Chastre J, Dreyfuss D, Mentec H, Carlet J, Brun-Buisson C, Lemaire F, Brochard L. Prevalence, etiologies and outcome of the acute respiratory distress syndrome among hypoxemic ventilated patients. SRLF Collaborative Group on Mechanical Ventilation. Societe de Reanimation de Langue Francaise. Intensive Care Med 1999, 25:920-929. 10.1007/s001340050983, 10501746.
5. Vincent JL, Akca S, De Mendonca A, Haji-Michael P, Sprung C, Moreno R, Antonelli M, Suter PM,. assessment SWGSof The epidemiology of acute respiratory failure in critically ill patients(*). Chest 2002, 121:1602-1609. 10.1378/chest.121.5.1602, 12006450, assessment SWGSof.
6. Vincent JL, Sakr Y, Ranieri VM. Epidemiology and outcome of acute respiratory failure in intensive care unit patients. Crit Care Med 2003, 31:S296-S299. 10.1097/01.CCM.0000057906.89552.8F, 12682455.
7. Esteban A, Anzueto A, Frutos F, Alia I, Brochard L, Stewart TE, Benito S, Epstein SK, Apezteguia C, Nightingale P, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA 2002, 287:345-355. 10.1001/jama.287.3.345, 11790214.
8. Behrendt CE. Acute respiratory failure in the United States: incidence and 31-day survival. Chest 2000, 118:1100-1105. 10.1378/chest.118.4.1100, 11035684.
9. Hedger MP, Winnall WR, Phillips DJ, de Kretser DM. The regulation and functions of activin and follistatin in inflammation and immunity. Vitam Horm 2011, 85:255-297.
10. Jones KL, de Kretser DM, Clarke IJ, Scheerlinck JP, Phillips DJ. Characterisation of the rapid release of activin A following acute lipopolysaccharide challenge in the ewe. J Endocrinol 2004, 182:69-80. 10.1677/joe.0.1820069, 15225132.
11. Jones KL, Mansell A, Patella S, Scott BJ, Hedger MP, de Kretser DM, Phillips DJ. Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc Natl Acad Sci USA 2007, 104:16239-16244. 10.1073/pnas.0705971104, 2042191, 17911255.
12. Nakamura T, Takio K, Eto Y, Shibai H, Titani K, Sugino H. Activin-binding protein from rat ovary is follistatin. Science 1990, 247:836-838. 10.1126/science.2106159, 2106159.
13. Sugino K, Kurosawa N, Nakamura T, Takio K, Shimasaki S, Ling N, Titani K, Sugino H. Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell. J Biol Chem 1993, 268:15579-15587.
14. Aoki F, Kurabayashi M, Hasegawa Y, Kojima I. Attenuation of bleomycin-induced pulmonary fibrosis by follistatin. Am J Respir Crit Care Med 2005, 172:713-720. 10.1164/rccm.200412-1620OC, 15976370.
15. Wu H, Chen Y, Winnall WR, Phillips DJ, Hedger MP. Acute regulation of activin A and its binding protein, follistatin, in serum and tissues following lipopolysaccharide treatment of adult male mice. Am J Physiol Regul Integr Comp Physiol 2012, 303:R665-R675. 10.1152/ajpregu.00478.2011, 22855279.
16. Apostolou E, Stavropoulos A, Sountoulidis A, Xirakia C, Giaglis S, Protopapadakis E, Ritis K, Mentzelopoulos S, Pasternack A, Foster M, et al. Activin-A overexpression in the murine lung causes pathology that simulates acute respiratory distress syndrome. Am J Respir Crit Care Med 2012, 185:382-391. 10.1164/rccm.201105-0784OC, 22161160.
17. Michel U, Ebert S, Phillips D, Nau R. Serum concentrations of activin and follistatin are elevated and run in parallel in patients with septicemia. Eur J Endocrinol 2003, 148:559-564. 10.1530/eje.0.1480559, 12720540.
18. Baccarelli A, Morpurgo PS, Corsi A, Vaghi I, Fanelli M, Cremonesi G, Vaninetti S, Beck-Peccoz P, Spada A. Activin A serum levels and aging of the pituitary-gonadal axis: a cross-sectional study in middle-aged and elderly healthy subjects. Exp Gerontol 2001, 36:1403-1412. 10.1016/S0531-5565(01)00117-6, 11602213.
19. Loria P, Petraglia F, Concari M, Bertolotti M, Martella P, Luisi S, Grisolia C, Foresta C, Volpe A, Genazzani AR, Carulli N. Influence of age and sex on serum concentrations of total dimeric activin A. Eur J Endocrinol 1998, 139:487-492. 10.1530/eje.0.1390487, 9849812.
20. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994, 149:818-824. 10.1164/ajrccm.149.3.7509706, 7509706.
21. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270:2957-2963. 10.1001/jama.1993.03510240069035, 8254858.
22. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on " sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med 1998, 26:1793-1800. 10.1097/00003246-199811000-00016, 9824069.
23. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
24. Knight PG, Muttukrishna S, Groome NP. Development and application of a two-site enzyme immunoassay for the determination of 'total' activin-A concentrations in serum and follicular fluid. J Endocrinol 1996, 148:267-279. 10.1677/joe.0.1480267, 8699141.
25. Ludlow H, Phillips DJ, Myers M, McLachlan RI, de Kretser DM, Allan CA, Anderson RA, Groome NP, Hyvonen M, Duncan WC, Muttukrishna S. A new 'total' activin B enzyme-linked immunosorbent assay (ELISA): development and validation for human samples. Clin Endocrinol (Oxf) 2009, 71:867-873. 10.1111/j.1365-2265.2009.03567.x, 19486020.
26. O'Connor AE, McFarlane JR, Hayward S, Yohkaichiya T, Groome NP, de Kretser DM. Serum activin A and follistatin concentrations during human pregnancy: a cross-sectional and longitudinal study. Hum Reprod 1999, 14:827-832. 10.1093/humrep/14.3.827, 10221721.
27. Steyerberg EW, Bleeker SE, Moll HA, Grobbee DE, Moons KG. Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J Clin Epidemiol 2003, 56:441-447. 10.1016/S0895-4356(03)00047-7, 12812818.
28. Steyerberg EW, Harrell FE, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001, 54:774-781. 10.1016/S0895-4356(01)00341-9, 11470385.
29. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172. discussion 207-112, 10.1002/sim.2929, 17569110.
30. Jones KL, de Kretser DM, Patella S, Phillips DJ. Activin A and follistatin in systemic inflammation. Mol Cell Endocrinol 2004, 225:119-125. 10.1016/j.mce.2004.07.010, 15451576.
31. Nusing RM, Barsig J. Induction of prostanoid, nitric oxide, and cytokine formation in rat bone marrow derived macrophages by activin A. Br J Pharmacol 1999, 127:919-926. 10.1038/sj.bjp.0702626, 1566097, 10433499.
32. Schwall RH, Robbins K, Jardieu P, Chang L, Lai C, Terrell TG. Activin induces cell death in hepatocytes in vivo and in vitro. Hepatology 1993, 18:347-356.
33. Zipori D, Barda-Saad M. Role of activin A in negative regulation of normal and tumor B lymphocytes. J Leukoc Biol 2001, 69:867-873.
34. Hedger MP, Drummond AE, Robertson DM, Risbridger GP, de Kretser DM. Inhibin and activin regulate [3H]thymidine uptake by rat thymocytes and 3T3 cells in vitro. Mol Cell Endocrinol 1989, 61:133-138. 10.1016/0303-7207(89)90198-6, 2501119.
35. Ogawa K, Funaba M, Mathews LS, Mizutani T. Activin A stimulates type IV collagenase (matrix metalloproteinase-2) production in mouse peritoneal macrophages. J Immunol 2000, 165:2997-3003.
36. Yndestad A, Ueland T, Oie E, Florholmen G, Halvorsen B, Attramadal H, Simonsen S, Froland SS, Gullestad L, Christensen G, et al. Elevated levels of activin A in heart failure: potential role in myocardial remodeling. Circulation 2004, 109:1379-1385. 10.1161/01.CIR.0000120704.97934.41, 14993131.
37. Phillips DJ, Brauman JN, Mason AJ, de Kretser DM, Hedger MP. A sensitive and specific in vitro bioassay for activin using a mouse plasmacytoma cell line, MPC-11. J Endocrinol 1999, 162:111-116. 10.1677/joe.0.1620111, 10396027.
38. Brown CW, Li L, Houston-Hawkins DE, Matzuk MM. Activins are critical modulators of growth and survival. Mol Endocrinol 2003, 17:2404-2417. 10.1210/me.2003-0051, 14551263.
39. Nusing RM, Barsig J. Inflammatory potency of activin A. Effect on prostanoid and nitric oxide formation. Adv Exp Med Biol 1997, 407:243-248. 10.1007/978-1-4899-1813-0_36, 9321959.
40. Nusing RM, Mohr S, Ullrich V. Activin A and retinoic acid synergize in cyclooxygenase-1 and thromboxane synthase induction during differentiation of J774.1 macrophages. Eur J Biochem 1995, 227:130-136. 10.1111/j.1432-1033.1995.tb20368.x, 7851378.
41. Yamashita S, Maeshima A, Kojima I, Nojima Y. Activin A is a potent activator of renal interstitial fibroblasts. J Am Soc Nephrol 2004, 15:91-101. 10.1097/01.ASN.0000103225.68136.E6, 14694161.
42. Dohi T, Ejima C, Kato R, Kawamura YI, Kawashima R, Mizutani N, Tabuchi Y, Kojima I. Therapeutic potential of follistatin for colonic inflammation in mice. Gastroenterology 2005, 128:411-423. 10.1053/j.gastro.2004.11.063, 15685552.
43. Hardy CL, Lemasurier JS, Olsson F, Dang T, Yao J, Yang M, Plebanski M, Phillips DJ, Mollard R, Rolland JM, O'Hehir RE. Interleukin-13 regulates secretion of the tumor growth factor-{beta} superfamily cytokine activin A in allergic airway inflammation. Am J Respir Cell Mol Biol 2010, 42:667-675. 10.1165/rcmb.2008-0429OC, 19635933.
44. Patella S, Phillips DJ, Tchongue J, de Kretser DM, Sievert W. Follistatin attenuates early liver fibrosis: effects on hepatic stellate cell activation and hepatocyte apoptosis. Am J Physiol Gastrointest Liver Physiol 2006, 290:G137-G144.
45. Wankell M, Munz B, Hubner G, Hans W, Wolf E, Goppelt A, Werner S. Impaired wound healing in transgenic mice overexpressing the activin antagonist follistatin in the epidermis. EMBO J 2001, 20:5361-5372. 10.1093/emboj/20.19.5361, 125651, 11574468.
46. Hashimoto O, Nakamura T, Shoji H, Shimasaki S, Hayashi Y, Sugino H. A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells. Endocytotic degradation of activin and its acceleration by follistatin associated with cell-surface heparan sulfate. J Biol Chem 1997, 272:13835-13842. 10.1074/jbc.272.21.13835, 9153241.
47. Matzuk MM, Kumar TR, Vassalli A, Bickenbach JR, Roop DR, Jaenisch R, Bradley A. Functional analysis of activins during mammalian development. Nature 1995, 374:354-356. 10.1038/374354a0, 7885473.
48. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet WS, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010, 142:531-543. 10.1016/j.cell.2010.07.011, 20723755.
49. Tisdale MJ. Reversing cachexia. Cell 2010, 142:511-512. 10.1016/j.cell.2010.08.004, 20723750.
50. Tsuchida K, Nakatani M, Uezumi A, Murakami T, Cui X. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocr J 2008, 55:11-21. 10.1507/endocrj.KR-110, 17878607.